182 related articles for article (PubMed ID: 32661647)
1. Emerging echinocandin-resistant Candida albicans and glabrata in Switzerland.
Coste AT; Kritikos A; Li J; Khanna N; Goldenberger D; Garzoni C; Zehnder C; Boggian K; Neofytos D; Riat A; Bachmann D; Sanglard D; Lamoth F;
Infection; 2020 Oct; 48(5):761-766. PubMed ID: 32661647
[TBL] [Abstract][Full Text] [Related]
2. Accuracy of Sensititre YeastOne echinocandins epidemiological cut-off values for identification of FKS mutant Candida albicans and Candida glabrata: a ten year national survey of the Fungal Infection Network of Switzerland (FUNGINOS).
Kritikos A; Neofytos D; Khanna N; Schreiber PW; Boggian K; Bille J; Schrenzel J; Mühlethaler K; Zbinden R; Bruderer T; Goldenberger D; Pfyffer G; Conen A; Van Delden C; Zimmerli S; Sanglard D; Bachmann D; Marchetti O; Lamoth F;
Clin Microbiol Infect; 2018 Nov; 24(11):1214.e1-1214.e4. PubMed ID: 29909005
[TBL] [Abstract][Full Text] [Related]
3. FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia.
Beyda ND; John J; Kilic A; Alam MJ; Lasco TM; Garey KW
Clin Infect Dis; 2014 Sep; 59(6):819-25. PubMed ID: 24879785
[TBL] [Abstract][Full Text] [Related]
4. Abdominal candidiasis is a hidden reservoir of echinocandin resistance.
Shields RK; Nguyen MH; Press EG; Clancy CJ
Antimicrob Agents Chemother; 2014 Dec; 58(12):7601-5. PubMed ID: 25288081
[TBL] [Abstract][Full Text] [Related]
5. Discontinuation of echinocandin and azole treatments led to the disappearance of an FKS alteration but not azole resistance during clonal Candida glabrata persistent candidaemia.
Imbert S; Castain L; Pons A; Jacob S; Meyer I; Palous M; Vezinet C; Langeron O; Hennequin C; Monsel A; Fekkar A
Clin Microbiol Infect; 2016 Oct; 22(10):891.e5-891.e8. PubMed ID: 27484020
[TBL] [Abstract][Full Text] [Related]
6. Echinocandins Compared to Fluconazole for Candidemia of a Urinary Tract Source: A Propensity Score Analysis.
Cuervo G; Garcia-Vidal C; Puig-Asensio M; Vena A; Meije Y; Fernández-Ruiz M; González-Barberá E; Blanco-Vidal MJ; Manzur A; Cardozo C; Gudiol C; Montejo JM; Pemán J; Ayats J; Aguado JM; Muñoz P; Marco F; Almirante B; Carratalà J;
Clin Infect Dis; 2017 May; 64(10):1374-1379. PubMed ID: 28329281
[TBL] [Abstract][Full Text] [Related]
7. Effect of initial antifungal therapy on mortality among patients with bloodstream infections with different Candida species and resistance to antifungal agents: A multicentre observational study by the Turkish Fungal Infections Study Group.
Doğan Ö; Yeşilkaya A; Menekşe Ş; Güler Ö; Karakoç Ç; Çınar G; Kapmaz M; Aydın M; Keske Ş; Şahin S; Hacıseyitoğlu D; Yalçın D; Tekin S; Ataç N; Albayrak Ö; Aksu ED; Can F; Ergönül Ö
Int J Antimicrob Agents; 2020 Jul; 56(1):105992. PubMed ID: 32335275
[TBL] [Abstract][Full Text] [Related]
8. Global analysis of the evolution and mechanism of echinocandin resistance in Candida glabrata.
Singh-Babak SD; Babak T; Diezmann S; Hill JA; Xie JL; Chen YL; Poutanen SM; Rennie RP; Heitman J; Cowen LE
PLoS Pathog; 2012; 8(5):e1002718. PubMed ID: 22615574
[TBL] [Abstract][Full Text] [Related]
9. Antifungal drug susceptibility, molecular basis of resistance to echinocandins and molecular epidemiology of fluconazole resistance among clinical Candida glabrata isolates in Kuwait.
Al-Baqsami ZF; Ahmad S; Khan Z
Sci Rep; 2020 Apr; 10(1):6238. PubMed ID: 32277126
[TBL] [Abstract][Full Text] [Related]
10. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
11. Recurrent episodes of candidemia due to Candida glabrata with a mutation in hot spot 1 of the FKS2 gene developed after prolonged therapy with caspofungin.
Durán-Valle MT; Gago S; Gómez-López A; Cuenca-Estrella M; Jiménez Díez-Canseco L; Gómez-Garcés JL; Zaragoza O
Antimicrob Agents Chemother; 2012 Jun; 56(6):3417-9. PubMed ID: 22391532
[TBL] [Abstract][Full Text] [Related]
12. Rapid emergence of echinocandin resistance in Candida glabrata resulting in clinical and microbiologic failure.
Lewis JS; Wiederhold NP; Wickes BL; Patterson TF; Jorgensen JH
Antimicrob Agents Chemother; 2013 Sep; 57(9):4559-61. PubMed ID: 23817368
[TBL] [Abstract][Full Text] [Related]
13. Positions and numbers of FKS mutations in Candida albicans selectively influence in vitro and in vivo susceptibilities to echinocandin treatment.
Lackner M; Tscherner M; Schaller M; Kuchler K; Mair C; Sartori B; Istel F; Arendrup MC; Lass-Flörl C
Antimicrob Agents Chemother; 2014 Jul; 58(7):3626-35. PubMed ID: 24733467
[TBL] [Abstract][Full Text] [Related]
14. Initial Treatment of Cancer Patients with Fluconazole-Susceptible Dose-Dependent Candida glabrata Fungemia: Better Outcome with an Echinocandin or Polyene Compared to an Azole?
Le A; Farmakiotis D; Tarrand JJ; Kontoyiannis DP
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584138
[TBL] [Abstract][Full Text] [Related]
15. Breakthrough candidemia due to multidrug-resistant Candida glabrata during prophylaxis with a low dose of micafungin.
Bizerra FC; Jimenez-Ortigosa C; Souza AC; Breda GL; Queiroz-Telles F; Perlin DS; Colombo AL
Antimicrob Agents Chemother; 2014; 58(4):2438-40. PubMed ID: 24468776
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of echinocandin antifungal drug resistance.
Perlin DS
Ann N Y Acad Sci; 2015 Sep; 1354(1):1-11. PubMed ID: 26190298
[TBL] [Abstract][Full Text] [Related]
17. Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata.
Bader JC; Lakota EA; Flanagan S; Ong V; Sandison T; Rubino CM; Bhavnani SM; Ambrose PG
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29555634
[TBL] [Abstract][Full Text] [Related]
18. Resistance to echinocandin antifungal agents in the United Kingdom in clinical isolates of Candida glabrata: Fifteen years of interpretation and assessment.
Fraser M; Borman AM; Thorn R; Lawrance LM
Med Mycol; 2020 Feb; 58(2):219-226. PubMed ID: 31111912
[TBL] [Abstract][Full Text] [Related]
19. Low level of antifungal resistance of Candida glabrata blood isolates in Turkey: Fluconazole minimum inhibitory concentration and FKS mutations can predict therapeutic failure.
Arastehfar A; Daneshnia F; Salehi M; Yaşar M; Hoşbul T; Ilkit M; Pan W; Hagen F; Arslan N; Türk-Dağı H; Hilmioğlu-Polat S; Perlin DS; Lass-Flörl C
Mycoses; 2020 Sep; 63(9):911-920. PubMed ID: 32413170
[TBL] [Abstract][Full Text] [Related]
20. Monitoring Antifungal Resistance in a Global Collection of Invasive Yeasts and Molds: Application of CLSI Epidemiological Cutoff Values and Whole-Genome Sequencing Analysis for Detection of Azole Resistance in Candida albicans.
Castanheira M; Deshpande LM; Davis AP; Rhomberg PR; Pfaller MA
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
